Last updated: June 1, 2026
Fexofenadine Hydrochloride Hives Suppliers: API, Intermediates, and Finished-Dose Sources for OTC Access
Who supplies fexofenadine hydrochloride for hives treatment in the US and globally?
Fexofenadine hydrochloride (used for hives, i.e., chronic urticaria) has a mature commercial supply chain covering (1) API, (2) key intermediates, and (3) finished-dose tablets and oral suspensions in OTC and prescription channels. Suppliers typically fall into three procurement categories: API manufacturers (including compliant DMFs), intermediate producers (for contract manufacturing and API cost control), and finished-dose manufacturers (for branded and generic supply).
Procurement map
| Supply tier | What buyers source | Typical contracting model | Main compliance artifacts |
|---|---|---|---|
| API | Fexofenadine hydrochloride | API supply agreement, long-term supply | US DMF/EDMF, CEPs, GMP certificates |
| Intermediates | Key intermediates for API synthesis | Contract manufacturing, captive/approved vendors | GMP for intermediate steps where applicable |
| Finished dose | Tablets and oral dosage forms | Contract manufacturing (CMO) or finished-goods purchase | cGMP for drug product, batch records, CoA per lot |
Finished-dose supply is commonly diversified among multiple CMOs and finished-goods distributors, while API is concentrated in fewer qualified producers because DMF-based qualification and impurity control drive entry barriers.
What API manufacturers supply fexofenadine hydrochloride (DMF holders) for antihistamine generics?
The practical supplier universe for fexofenadine API is defined by firms that hold or support drug master files and can pass regulatory and impurity acceptance for generic dossiers. For buyers, the relevant question is less “who makes it” and more “who is already qualified into global dossier workflows.”
Common supplier profile (business-relevant)
- Multi-product fine-chemical or active-ingredient manufacturers with documented impurity control for chiral and salt form consistency.
- Firms with established regulatory submissions (US DMF or equivalent) supporting generic product approvals.
- Contracting willingness for batch consistency, controlled particle size, and water/moisture handling that affects stability of finished tablets.
Which companies manufacture fexofenadine hydrochloride finished tablets and oral formulations?
Finished-dose manufacturers supply OTC and generic channels for hives and related allergic conditions. Procurement usually splits between:
- Direct brand/generic finished goods from vertically integrated manufacturers, and
- CMO manufacturing under private label or abbreviated approval strategies.
Dosage-form scope most relevant to “hives”
| Dosage form | Typical market positioning | Common buyer use case |
|---|---|---|
| Tablets (commonly 30 mg, 60 mg) | OTC and generic | Low-risk replenishment inventory |
| Higher-dose tablets/special formulations | Prescription and OTC crossover | Dossier-specific formulation and stability needs |
| Oral suspension (where marketed) | Pediatric or dosing flexibility | Higher formulation complexity, stricter excipient controls |
What intermediates and starting materials suppliers support fexofenadine hydrochloride production?
Downstream supply depends on upstream intermediate availability and impurity profiles. Buyers typically qualify intermediate suppliers through:
- consistent spec adherence (assay and impurities),
- traceability of starting materials,
- and documented GMP for steps affecting impurity formation.
Intermediate sourcing is usually less visible publicly than finished-dose and DMF-holder API suppliers, but the risk is the same for all generics: if upstream impurity specs drift, the finished product can fail stability or release criteria.
What contract manufacturing organizations (CMOs) make fexofenadine tablets for generic companies?
CMOs in tablet manufacturing typically compete on:
- throughput and packaging line capacity (bottles, blister),
- stability support data and accelerated/long-term protocols,
- and change-control discipline (equipment, suppliers, compression profiles).
Key technical levers buyers screen
- Tablet hardness and friability specs tied to formulation process
- Moisture sensitivity control for hydrochloride salt stability
- Blend uniformity and low batch-to-batch variance
Which supplier relationships matter most for supply continuity in fexofenadine hydrochloride hives products?
In practice, supply continuity depends on:
- single-site vs multi-site manufacturing strategy for API and drug product,
- qualification lead times for dossier and impurity acceptance,
- and documented scalability (pilot-to-commercial batch transfer).
Buyer risk checkpoints
| Risk area | What to check in supplier documentation | Why it matters |
|---|---|---|
| API impurity control | CoA impurity trends, comparability data, method validation status | Generic release depends on impurity acceptance |
| Salt form and solid-state control | Polymorph/particle size control evidence | Affects dissolution and stability |
| Batch transfer | Tech transfer package completeness and deviation history | Avoids failed batches during scale-up |
| Packaging and labeling | Serialization readiness and packaging line validation | Prevents release delays in commerce |
How should procurement teams shortlist fexofenadine hydrochloride suppliers for hives launches?
Shortlisting is a qualification exercise with two tracks running in parallel:
- Regulatory qualification track: DMF alignment, right references for generic dossiers, and ability to support regulatory submissions.
- Commercial reliability track: production capacity, fill rate history, and lead-time commitments.
A practical shortlist structure
- At least two API supply options qualified on regulatory and quality compatibility.
- One or more finished-dose CMOs or finished-goods partners for contingency manufacturing.
- Backup intermediate sources when possible, especially where intermediates are prone to sourcing constraints.
Key Takeaways
- Fexofenadine hydrochloride hives products rely on a regulated API supply chain where DMF-based qualification and impurity control determine supplier usability.
- Supplier selection should be structured by regulatory compatibility (API) and manufacturing reliability (drug product), not by generic “manufacturer availability.”
- Buyers should treat upstream intermediate stability and salt form control as release-critical, then qualify contingency sources early to reduce launch and replenishment risk.
- Finished-dose availability is typically more diversified than API, which concentrates risk and drives lead-time and pricing dynamics.
FAQs
- What specs matter most when sourcing fexofenadine hydrochloride API for generic hives products?
- How do API impurity profiles affect generic release for fexofenadine hydrochloride tablets?
- Which drug product packaging formats are most commonly used for OTC fexofenadine hives dosing?
- What CMO capabilities are most critical for fexofenadine tablet compression and stability?
- How do change-control and batch transfer requirements impact supplier switching for fexofenadine hydrochloride?
References
- FDA. Drug Master Files (DMFs). US Food and Drug Administration.
- FDA. Current Good Manufacturing Practice (CGMP) for Finished Pharmaceuticals. US Food and Drug Administration.
- FDA. ANDA Regulatory Information. US Food and Drug Administration.
